[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:chronic-lymphocytic-leukemia:cd19-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Chronic Lymphocytic Leukemia","CD19 Gene",13,[8,16,23,30,36,42,48,55,61,67,73,79,86],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07321652","Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL\u002FSLL",[12],"Phase 3","RECRUITING","2026-08-26T02:19:14.560989Z","2026-06-17T02:29:30.059389Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:24.494016Z","2026-07-05T05:32:16.752213Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",[27],"Phase 1","2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.649787Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT05702853","Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed\u002FRefractory NHL, CLL\u002FSLL",[20],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:28.285448Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04892277","CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed\u002FRefractory B Cell Malignancies",[27],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.592999Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06227026","Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed\u002FRefractory CD19+ Malignancies",[27],"2026-08-26T02:15:11.740957Z","2026-04-29T02:57:57.116949Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[52],"Phase 2","2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[27],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT03666000","Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed\u002FRefractory (r\u002Fr) Non-Hodgkin Lymphoma (NHL) and r\u002Fr B-cell Acute Lymphoblastic Leukemia (B-ALL)",[27],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:27.435593Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[20],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05281809","Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",[52],"2026-08-26T02:19:03.581490Z","2026-04-29T02:57:57.140676Z",{"nct_id":80,"title":81,"phases":82,"status":83,"updated_at":84,"content_modified":85},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[27],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z",{"nct_id":87,"title":88,"phases":89,"status":90,"updated_at":91,"content_modified":92},"NCT03331198","Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:36:24.364783Z","2026-05-05T02:43:29.139125Z"]